Greenwood Capital Associates LLC Decreases Holdings in Novo Nordisk A/S (NYSE:NVO)

Greenwood Capital Associates LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 93.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,490 shares of the company’s stock after selling 32,974 shares during the period. Greenwood Capital Associates LLC’s holdings in Novo Nordisk A/S were worth $296,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. GQG Partners LLC lifted its position in Novo Nordisk A/S by 654.6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after acquiring an additional 3,151,584 shares during the last quarter. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its stake in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Acadian Asset Management LLC increased its stake in Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after purchasing an additional 1,155,313 shares in the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $98,765,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Up 0.4 %

NYSE:NVO opened at $110.15 on Wednesday. The firm has a market capitalization of $494.30 billion, a P/E ratio of 37.72, a PEG ratio of 1.46 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company’s fifty day moving average price is $123.24 and its 200-day moving average price is $130.76. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.